Raymond James Financial’s INmune Bio INMB Stock Holding History

Raymond James Financial’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$230K	Sell	203,245 -7,433	-4%	-$10.6K	﹤0.01%	4817
2025 Q4	$329K	Sell	210,678 -57,782	-22%	-$103K	﹤0.01%	4514
2025 Q3	$556K	Sell	268,460 -65,017	-19%	-$149K	﹤0.01%	4062
2025 Q2	$770K	Sell	333,477 -48,564	-13%	-$356K	﹤0.01%	3737
2025 Q1	$2.98M	Sell	382,041 -93,510	-20%	-$743K	﹤0.01%	2691
2024 Q4	$2.22M	Buy	+475,551	New	+$2.48M	﹤0.01%	2889

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Raymond James Financial's INMB Position: Q1 2026 in Review

Raymond James Financial reduced its INmune Bio (INMB) stake by 3.5% in Q1 2026, selling an estimated $10.6K and leaving 203,245 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #4817.

Raymond James Financial first reported a position in INMB in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.98M in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

Raymond James Financial held 203,245 shares of INmune Bio worth $230K as of Q1 2026.
Raymond James Financial sold 7,433 INmune Bio shares in Q1 2026, an estimated $10.6K.
INmune Bio made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4817 holding.
Raymond James Financial first reported a position in INmune Bio in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's INmune Bio position peaked at $2.98M in Q1 2025.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.